Cell and Gene Therapy: Why a Cure Isn't Enough
with Andy Moye · Co-Founder & CEO, Glidepath Health
Cell and gene therapies can cure disease, but a cure only matters if the patient can actually get it. Andy Moye, PhD, co-founder and CEO of Glidepath Health, joins Chris Hutchins on the operational gap between an advanced therapy and the patient who needs it: scheduling, travel, reimbursement, and fragmented data. A former US Naval Flight Officer and author of From Bunker Hill to the Boardroom, Andy also unpacks the leadership habits behind empowered teams, clear intent, and better decisions under pressure.
Cell and gene therapies can cure disease, but a cure only matters if the patient can actually get it. Andy Moye, PhD, co-founder and CEO of Glidepath Health, joins Chris Hutchins on the operational gap between an advanced therapy and the patient who needs it: scheduling, travel, reimbursement, and fragmented data. A former US Naval Flight Officer and author of From Bunker Hill to the Boardroom, Andy also unpacks the leadership habits behind empowered teams, clear intent, and better decisions under pressure.
Andy traces his path from the US Navy into cancer diagnostics and advanced therapies, including digital pathology at Paige, and explains what changed in oncology over the last 25 years. The conversation then turns to cell and gene therapies, how CRISPR based treatments can effectively cure diseases like sickle cell, and why most eligible patients still never receive them.
Chris and Andy work through the three barriers between a working therapy and the patient: cost, geography, and a year-long manual scheduling cascade. Andy describes what Glidepath is building to orchestrate that delivery, where AI belongs in prior authorization and reimbursement, the fragmented data problem underneath it all, and the leadership habits he carried from the military into a startup.
The science works; the delivery fails patients. Andy says 80 to 90 percent of patients eligible for CAR T therapy do not get it, lost to cost, distance from academic centers, and a scheduling process that can run more than a year on spreadsheets.
The bottleneck has moved. In 2020 one cell and gene therapy was approved; today there are 48, with over 300 late-stage US trials. The health system is not built to manage that volume, and Glidepath builds an AI orchestration layer that turns each therapy protocol into automated tasks.
AI asymmetry in reimbursement. Insurers already use AI to screen prior authorizations at scale, while hospitals mostly do not, which Andy calls bringing a knife to a gunfight. He sees AI generating the clinical letter of necessity and chasing status so patients start therapy sooner.
Fragmented data is the ground truth problem. Records still do not follow the patient across systems, and Andy aims to put all the data for one therapy in one place and make it visible to research, pharma, and the patient.
Judge decisions, not outcomes. Drawing on his book and military after-action reviews, Andy argues leaders should examine the judgment behind a result, not only the result, to build better decision making over time.
Figures and examples in this episode reflect Andy Moye experience and Glidepath Health observations and are offered as leadership insight. They are not validated outcomes and are not legal, clinical, billing or compliance advice for any specific organization.
Andy Moye, PhD, is the co-founder and CEO of Glidepath Health, which builds AI to orchestrate the delivery of cell and gene therapies. A former US Naval Flight Officer, he spent more than two decades in cancer diagnostics and advanced therapies, including digital pathology at Paige, and holds a PhD in health economics. He is the author of From Bunker Hill to the Boardroom: Battle-Tested Leadership for Today Executives. Connect with him on LinkedIn.
Chris Hutchins: Welcome back to the Signal Room. I'm Chris Hutchins. Quick thing before we start, I wrote a book. It's called Beneath the Signal, and it's about the human work behind trusted data and responsible AI and healthcare. Search Beneath the Signal on Amazon now and pick up your copy. Okay, here's our episode. Some of the most remarkable therapies in medicine right now are cell and gene therapies. Treatments that can actually cure a disease, not just manage it, but a cure only matters if the patient can actually get it. And that turns out to be one of the hardest logistics problems in healthcare. My guest today has spent his career at that edge cancer diagnostics, biotechnology, cell and gene therapy. He's the author of a leadership book from Bunker Hill to the Boardroom. And he's now the founder of Glidepath Health, where he's building AI to take on the scheduling, coordination, and reimbursement, and the fragmented data that stands between these therapies and the people who really need them. Andy, welcome to the Signal Room.
Andy Moye: Thanks so much, Chris. It's a pleasure to be here. Appreciate it.
Chris Hutchins: Before we get in too much to the details, I'd love to hear a little bit about, you know, what's your why? You'll give people a version of who you are and how you ended up here and working and building Glidepath Health.
Andy Moye: No, thank you. It's been kind of a crazy journey, you know, for me, particularly in healthcare and in service. And of course, you know, I start my career in the military, and uh you mentioned my book, and so that's kind of a running theme in my family. My dad was in the military and he was in Vietnam, and I have this long family history that goes back to the Revolutionary War, and so that's a lot of what that's about. But it's it's really kind of um, you know, bent on service. You know, I sort of have always, from an early age, always kind of wanted to serve people. I found my purpose and my why in trying to help as many people as you can. And when you're young in the military, it's a great way to do that. You're serving a higher cause, kind of get out, you kind of have a, you know, like a lot of veterans, it's a tough transition sometimes, but you think, well, how can I continue to impact people? And I kind of got into this crazy space of diagnostics, um, really because I'm, you know, there were some companies at the time that hired a lot of veterans coming out of the military. And so got into the lab and diagnostic space and very quickly realized that if you were somebody who wanted to try to solve problems, there was no shortage of problems in healthcare. You know, like the number of issues to from patient access to diagnosis to technology to you know, just any reimbursement and financial toxicities, but new technologies, like there really was, you know, for people whose sort of life uh and purposes around helping people, but also solving hard problems, it's an amazing space to be in. And so I kind of found myself over the course of the last 20 years, you know, continuing to develop, got a PhD in health economics along the way, just so I could better understand kind of the financial pieces of everything that we were building. But it really, how do we bring new technology into healthcare? And then I've obviously with AI, and we'll talk a lot about that, but how do we bring new technologies into healthcare in a way that gets more people access to these types of therapies and care and diagnostics and can help more people than the way we're doing it today? So that's really been my why the whole way. It's it's been how can I continue to influence and help people and use technology to do that?
Chris Hutchins: Yeah, that's amazing. And you know, before I say anything else, th thank you for your service. So let's take you back a little bit before the Glidepath piece of it and talk about your journey kind of coming through your career. So you start with you dealing with cancer diagnostics, biotech, cellar gene therapy, which is kind of enough for people to cut their teeth on, I would say, if you're if you're working on things from a build standpoint. But what made you think even consider leaving the executive seat to go build something like this?
Andy Moye: Yeah, you know, if you think about the last 25 years, and I'll kind of I'll kind of speak more specifically to cancer care in oncology because that's a lot of what I did. Although I just spent some time in some other areas. What's happened in the last 25 years really can't be overstated. Like, you know, and I have a really good friend who's sort of on the same mission, and he's an oncologist, a guy named Doug Flora, and he likes to say, and he wrote a great book too, and he likes to say there, and it's funny to hear this from a doctor, and I'll and I'll say it, and people will go, What? But he'll say, This isn't there's never been a better time in the world to have get a diagnosis of cancer. And what he means by that is that the technologies that have come in the past 20 years, and I'll just sort of rattle off, you know, next generation sequencing, the ability to sequence your genome, the ability to understand genetic uh germline, it's called germline uh markers uh that are part of your DNA that might cause cancer, the somatic oncodrivers, and then the drugs that then treat these very specific um, you know, oncodrivers of cancer have proliferated. And so what you've seen over time is the mortality rate overall from cancers uh coming down, right? And so I've kind of been part of that journey in a lot of ways. Early on in my career, I was part of this company. I worked with this doctor, luminary in oncology named Dan Von Hoff. And he had this theory in the early 2000s that you could do this, that you could do some genetic sequencing, that you could do some genetic markers, and that would actually tell the oncologist what drug to give. And I say this now, that's pretty standard of care now. But in 2006, 2007, this was voodoo. I mean, you know, absolute hierarchy, you know, get out. How dare you like because oncologists at the time had very much prescribed ways to treat, and it was chemo, radiation, surgery. This was it. This is what you got. And to say, oh, I'm gonna test you and understand what's driving this, and I'm gonna provide some drug that's actually gonna attack the cancer that way, was absolutely crazy. But this is, you know, over the last 20 years, that's you know, so I was part of that very early on, educating doctors about you know why this is important and continued on and then you know started to get into more of the diagnostic side, and which led me to a company called Paige. I was part of Phillips, you know, even before that. But you know, for the for the audience, this gets a little technical, but people think you go to the doctor or something happens and they tell you you have cancer. Yes, that's sort of the case, but really until they take some tissue from you, so you go get a mammogram. If you're a woman, you go get a mammogram. If you're a if you're a man, maybe you go have your PSA is too high, they want to do a prostate biopsy, they do the biopsy. They have to take tissue, and that tissue goes to a pathologist. The pathologist is a specialty trained doctor whose whole life it is to look under a microscope at slides and cells and make a determination of whether you have cancer or not or other diseases, but mainly cancer. And the challenge with that is it's complicated. You know, like it people are people. You know, you have a bad night, you don't get any sleep, you wake up in the morning, you have to look at 10 slides, 20 slides, 30 slides to find a couple of micrometers of cancer on a slide, you miss it. And we developed at Paige, um, which was a spin out of Memorial Sloan Kettering Cancer Center, this amazing technology to be able to digitize these slides. And now, once it's digital, Chris, and you know this, like once something's digital, you have access to those pixels, right? And you can use computer vision and machine learning to then train algorithms to do things and understand what's on those slides. And we did that at Paige, and we did something really cool. We got the first ever FDA-approved test essentially for the detection of prostate cancer. it was years before anybody else got another one. And really, today there's only two or three companies that have an FDA approval in pathology because it's so challenging to do. We published uh multiple nature medicine papers, new techniques. We published the first foundation model in digital pathology and something called Virchow. So, you know, that's that's really the kind of work, you know, cutting edge, right? Way out on the edge. But unfortunately, healthcare is still way back here, you know. And so I kind of think about my career as I, you know, kick, you know, pulling, pulling the healthcare system, kicking and screaming into the future. You know, that's kind of the way I feel
Chris Hutchins: the precision stuff. Maybe you could explain this a little bit, but the the stuff they were doing with radiation therapy, they were showing me the I don't remember what they called the thing, but it's like thousands and thousands of these tiny little pins basically that are moving in and out, and it actually is mapped to your cell structure and your tissue, and it blocks the radiation from hitting cells that it shouldn't hit.
Andy Moye: That's right. That's right.
Chris Hutchins: But it was so precise the way it was described, I was shocked. I'd never heard of that.
Andy Moye: Yeah, and things like gamma knife and you know, the radiation therapy side has come a long way for sure. Uh, but even, you know, again, on the medical oncology side, you know, the ability to, you know, prescribe specific drugs that go after a very specific, which we'll talk about, you know, the cell in gene therapy space, which is which is even more exciting. Um, but the ability to sort of really target these, you know, either proteins or antigens on the surface of the cells that that can attack and really you know create you know remission for most of these patients, and depending on the on the disease. So yeah, it's look, I mean, but that all said, the reality too, though, is the prevalence of the incidence of cancer continues to rise. So mortality is coming down, but we're finding it more often in younger people. You know, we won't get into speculation about all that. There's a lot of stuff to talk about that. In the veteran community, and we're talking about the veterans, actually, very, very high rate of cancer incidence, still kind of unknown. There's a lot of people kind of working on those things. A study just came out about flight attendants and pilots in the incidence of cancer because you know, high radiation doses, you're just at higher altitudes for longer than other people, and you just get more radiation exposure than you know the the average human being, and you have a higher incidence of cancer. So there's just things that are continuing in our in our society. But yeah, the great news for overall, the great message is you know, cancer is no longer the death sentence it used to be. Certainly there are some cancers that are not great, but generally uh a lot, most is very curable.
Chris Hutchins: But I wanted I don't want to skip too far ahead. I'd like to hear you, have you talked a little bit about the leadership book that you started? Where that kind of plays into it as well.
Andy Moye: So it's from Bunker Hill to the Boardroom, Battle Tested Leadership for today's executives. And it's a it is a leadership book. It's it tells some military history, goes back in my family history, but I was really trying to tie it, you know, Chris, you know, this from your experience, you know, you kind of get to a place in your career and you said, I kind of do know a couple things, you know, I think, you know, maybe I should I should impart some of that leadership, you know, pain that I went through. Um and it just was a really good able, you know, ability to be to for me to tell a story of um, you know, military service members in my family, my dad, me, great-great, great, great-grandgrandfathers, all the way back to the Revolutionary War, and kind of give people this idea around are there pillars of leadership that sort of stand that test of time and that are still applicable today's leaders? And and the book was really written, you know, a C-suite guy, a CEO, a COO absolutely can take something away from it. But I hope, you know, a frontline manager at Walmart also could, you know, could take something away from it. Because we do try in every chapter and every section to tie it back to today's issues, whether that's building a startup in AI, um, you know, whether that's the way you're doing organizational planning, you know, in a large company or whatever the case is, and say, you know, are there you know things to just sort of think about? When I think about leadership books, the best leadership books I've ever read, I don't remember the whole book. You know, I remember one or two things that I try to take away and use and maybe go back to that book every year or two and say, oh, what was that about? And then and then try to remember in my in my daily life. And so, you know, just to kind of kind of wrap that up, the three principles we talk about are uh purpose over vision. You know, I think there's, you know, leaders probably don't really understand their company's purpose. They don't understand their people's purpose. You know, in fact, your question at the top of the show was great. You know, what's your why, right? And I I try to get you know, all of my leaders to ask their people, what is your why? Why are you here? And then try to make sure that they understand how that why can tie to the company's purpose, right? And the company's mission, because that's important. And I think when you do that, you get engaged with employees. And secondly, it also helps you identify people that maybe aren't aligned, right? And I think when you have people who aren't aligned, it's probably good to find them a new opportunity in life, you know, those kind of things. Um, and then secondly, about this idea around being adaptive. And I, you know, we'll talk more about AI and technology. In today's world, being adaptive, I think it used to be like a nice to have. Today you have to be adaptive. Like you have to have adaptive intelligence as a leader. The ability to peer around corners, the ability to anticipate what's coming, and the and to know the difference between a pivot and an iteration. Like those are those are skills that I don't think leaders are taught enough. And it sort of comes with experience. It comes with you know intelligence for sure, but having a mindset, a flexible mindset, I think also helps. And then the last one, you know, something that's really important to me, and I uh I credit a guy named General Stanley McChrystal, who who was, you know, he was the the chair of the joints, you know, special operations command in Afghanistan and Iraq, and he wrote a great book called Team of Teams.
Chris Hutchins: One of my favorites.
Andy Moye: Yeah, and he was really generous, and he wrote the foreword to my book, um, you know, just because he really liked the premise. But it's really, you know, kind of taking off that idea around empowered teams, you know, being able to, you know, as leaders, especially as founders of companies, it's very um, you know, it's very, you really want to hold on control. You know, like you don't you don't want to give up any decisions, right? And as organizations get bigger, what ends up happening is the leader, the founder becomes the bottleneck, right? You become the problem because you're not empowering your teams to make decisions and move forward. And so that's sort of the third principle we really talk a lot about. And I think they're all applicable again to today's world, and hopefully people can look at the book and think the same.
Chris Hutchins: Because just having to flip that script and say, okay, we have to open up the communication piece of it. So everyone's kind of hearing things together that typically would have been heard at the top, and we figure out what to transmit down through through the ranks. That's a very different uh paradigm and you know how you guys navigate it. I mean, it's brilliant. You have to accept that there's a whole different um environment and there's a lot of different factors, and people have perspectives now they couldn't have had before, but they can now because of all the advancement in technology, et cetera. But a lot of it's just people stuff.
Andy Moye: You hit it right in the head there, too, because in today's world, especially generations younger than me, okay, I'm a Gen Xer, so like those generations, they want to they have access to all the information they want, so they want to know why. You know, they're you know, and I and I think older leaders, particularly the boomer generation, my dad, it was always just shut up, you know, do the thing, right? That was it. But you can't do that anymore. And so you exactly hit the red on the head. It's like the communication, the cascading communication from the top, and how that, and you know, we talk about in the book something called Commander's Intent, which is a which is a typical what was a common you know theme you talk about in the military, because the commander's intent helps every mission, every place, because you know, if the captain is in the middle of the battle and and gets hit, the sergeant has to pick up and know what to do, right? You know, I mean, so you can't not know what to do if you want to achieve the objective. So being able to communicate your commander's intent, which is also part of just communicating to people why we're doing things, they don't have to agree with you, you know, and half the people won't, right? But that's okay, right? As long as people actually will tell you, hey, I just want to know why we're doing it. I may not agree, but I'm gonna go do it. And I think you get a lot more engagement that way.
Chris Hutchins: Yeah, I think I think that's a great point. Talk about what actually has to happen from this patient qualifies to the therapies actually delivered. I that's a very different process than I think I probably have understood.
Andy Moye: It's a great, it's a great question. And you know, just to kind of define what we mean by cell in gene therapies, you know, and there's and you can treat a whole clock, you know, a lot of different diseases. We'll talk about cancer, we'll talk about sickle cell, we'll talk about blood disorders like thalassemia and things like this. But essentially, you know, and this is also when we talk about technology, over the past 10 years, and you know, Dr. Jennifer Doudna and a lot of the folks at MIT and others, you know, came up with these technologies to be able to edit genes, to edit DNA in a way that you can actually insert, you know, uh, you know, people are sort of familiar with GTCA, right? I won't get into all of that, but you're, you know, you have three billion bases and three billion base pairs, and they're all G or C or T or A or whatever. And the DNA is what they are, and they make you you're tall and you have brown hair and you have green eyes or whatever. But also sometimes the G should be a C. And if the G isn't a C in a certain spot, you get sickle cell disease as an example, right? And that's a genetic disorder. And there are thousands of genetic disorders. Most of them are rare diseases because these are things that like happen in the womb and they, you know, sperm beats egg, and you have a problem with, but essentially, these are genetic diseases, things like spinal muscular atrophy, for example, for babies. You know But you know, like sickle cell disease, to kind of stick with that, with that, is a debilitating lifelong disease. Because what ends up happening is the gene instead of the C creates tells the body to create cells, red blood cells, which should be kind of round and donut-shaped, uh, to be sort of half moons. And these half moons don't flow through the bloodstream very well, and they get clogged up like the traffic jam on the 405, right? You know, they all get clogged up, and you the patient be gets extraordinary pain, like just unbelievable pain, and it's a painful, awful disease that lasts, you know, a long time. And ultimately, you know, a lot of patients succumb to it. But today, you know, there are treatments on the market, two or three of them, one from Vertex, another from a company called bluebird bio, that allows you to essentially reboot. You know, for your IT guys out there, I'm gonna reboot the system. There's something wrong with my, I'm gonna reboot this thing. And how in the hell do you reboot the human body? Well, you do it by taking cells from the person and genetically modifying those cells in the way I just sort of described using this CRISPR you know technology, putting the C right instead of the G, right, and fixing that, and putting those cells back in such that the body now is like, oh, this is the new code. I got the update. You know, you gave me the update, fixed the bug, and I'm gonna now make new cells that are round and not have mid-shaped. And that works. That works. These patients essentially are cured and it's you know, not fully, sometimes it just kind of depends on what you do. But this is, and so you kind of, when you kind of say it that way, you're like, oh, yeah, okay, amazing. Let's let's do that. There's a lot of challenges to that. And I'll and I'll describe one other one other um example of these types of therapies is in cancer. So in cancer, you have um the problem, the reason that cancer, your body doesn't go after it like a virus or a cold or something, is that your cells are the ones that are going nuts. And so your immune system looks at a tumor, breast cancer tumor or blood disorder or something, and looks at those cells and goes, Well, that's Chris. I'm not gonna go after Chris, uh leave him alone, right? You know, he's oh Chris, those cells have gone nuts, but the but the immune, the human body, the immune system says, Well, that's not in a foreign invader. So I don't know what to do about that. I'm just gonna leave it alone. And so you know, researchers for years have been trying to figure out how to get our own body to attack these bad guys, right? And so that's another way, this process, you can actually pull these, what they call T cells, you can pull T cells out of the body, reprogram them to go after the cancer in your blood, and put those cells back in. That's something called CAR T therapy. And this is extraordinarily effective, especially for really bad recurrent or refractory, you know, leukemias and myelomas and things like that. This works. And there's a famous patient, her name is Emily Whitehead. She was a child when she had this disease. She was the first to ever get this type of therapy fully cured. She's in her 20s now, and um, you know, she has a whole foundation called the Emily Whitehead Foundation. But so these therapies work. They're amazing, right? And there's a world, Chris, in the next 10 years where no parent will worry about a genetic disorder for their child, right? Something debilitating that might have been either fatal or just debilitating for the rest of their lives. The ability to do gene therapy can fix these things, right? So, so I mean. The cures work, and that's the amazing thing about the science. The delivery, our healthcare system is failing these patients, right? And there's some statistics around you know 80 to 90 percent of the patients who are eligible for you know that CAR T therapy I just described, don't actually get the therapy. Now, why don't they get the therapy? There's kind of three big reasons why. One, these drugs, all of them, are half a million, a million, up to five million dollars each. So the financial piece of this is not trivial. Now, there's a reason they're that expensive because this is high science, right? This is really, you know, technically difficult. And, you know, for example, of sickle cell, if you pay $3 million to cure your sickle cell, the health economics actually works out better for the system. It actually, because that patient may have gone to the ER 50 times in their life, you know, whatever, or now you're eliminating all that kind of stuff, right? So these are really expensive drugs. The second problem that you have is these treatments all are given in big hospitals or health systems in big cities. But care, that's not where care is always given. You know, there's something like 75% of the cancer care in this country is given what they call a community or community oncologists versus big academic medical centers. But the community oncologists are not quite giving, they're not giving this therapy because it's complicated. And so patients are having to travel, and if they have to travel, they're not going to travel, you know, and sometimes these patients are elderly or whatever, they're just not gonna go. So you lose those patients in that way. And the third problem is is this logistics issue around scheduling. There's really it's such a complicated cascade of events that has to happen for this patient that sometimes is over a year long. And sometimes the patient can't wait a year, or sometimes they get too sick, uh, you know, all of those kind of things. And most of that, Chris, is operational, you know, just getting scheduling and you know, and helping the patient, or helping the infusion, making sure the infusion beds are there, the apheresis clinic is ready, or there's a drugs manufacturing slot, whatever. And so today, unfortunately, because these drugs are so new, there's no process. Everything's sort of done on spreadsheets and Google Docs and things like that. And so in the age of AI, and I like to give the example, you say to somebody, hey, go in your downloads folder and tell me how long it would take you to organize all that crap. You know, just you, you'd have to go in there. I want you to rename them, classify them properly, put them in the right folders, figure it all out. I'm not doing that. That's terrible. Ask Claude to do it. Claude will do it in 10 seconds, right? And so in today's world of AI and technology and LLMs, the ability, why we still have human beings trying to call and hey, is there a bed? And what hey, I need to get the patient in for a lab. And did the lab come in and running around and calling and phone calling and all stuff is insane, right? And so this is what we're doing with Glidepath is we are bringing this orchestration layer, technology and AI that takes these really complicated delivery protocols, breaks them down into tasks, automates the entire scheduling from end to end, and allows those providers to actually get more patients through the funnel. And if you get more patients through the funnel, you're actually improving patient outcomes because you're reducing the time to treat these patients are getting the care they need. And so we're, you know, I'm really, really passionate about this because this is like one of those places in healthcare that you can use technology today to get more patients' care that matters. And so that's really the opportunity here. And for the for the pharma companies, maybe just to round this out, for the pharma companies, it's the same sort of thing. Like what we're providing to them is the ability for them to have visibility and really sort of have a rapid learning cycle. You know, understand what's going on with their drugs, how patients are reacting, how patients are responding, have a hard time with long-term monitoring, are these patients doing well on the drug or not? And so having all the data in one place allows us to provide that data to pharma so that they can better understand how their drugs are doing and bring better, better therapies to market. Yeah.
Chris Hutchins: The bottleneck historically has been more the science than the processes and efficiencies around it. I think that's very different now from what I've been hearing. Certainly what you're what you're indicating, that that's kind of what you're saying too, right?
Andy Moye: Yeah, that that's exactly right. I mean, uh, you know, this is probably a terrible analogy, but like, you know, the ability to sort of split the atom was years before they made the bomb. Right? And so, know, like the practical operational delivery of some of these technologies has really been some of the challenge in healthcare. And, you know, you say, okay, I want to get, and also the biggest challenge, well, well, one of the things that contributes to this too is that every pharmaceutical company is proprietary, every biotech has their own drug, they all go through a clinical trial process that is unique. I mean, even though a lot of the ways this works is sort of similar, the protocols are all different. And so the way you have to deliver the care is all dependent on the way the clinical trial was um was delivered, the way the you know the FDA approved that specific drug in that specific setting and that specific indication for use. And so it becomes really overwhelming for the providers. To give you an example of this, in 2020, there was only one of these types of cell engine therapies approved. Today there's 48. There's 4,200 clinical trials ongoing globally. And in the US, there were over 300 late-stage clinical trials going on. And so the FDA, you're gonna probably see 20, 30, 40 of these drugs a year start to get approved. And the healthcare system is not set up to be able to manage this type of really complex. You know, think about what's happening in hospitals and health systems right now when AI kind of came out. Like, well, what do we do? We need governance committees, you know, you know, but when ChatGPT hit the market for about a year, right, you know, CIOs at health systems like were like deers at headlights, right? Like, what are we, what are we gonna do? You know, how do we, what happens now? And and trying to wrangle it and trying to get their doctors to stop, you know, taking pictures of, you know, like doing whatever they were doing to fix it. And so similar in cell gene therapy, this is just not an area where people have focused their attention. And so for us, we think it's definitely a place where the more we can solve this pain for the hospitals and health systems using technology, then the more opportunity there is to continue to build to scale, right? So the way I think about the technology is it has to be so scalable that we can take on 300, 400, 500 drugs, it doesn't matter. And we can take on as many patients as the hospital wants to, that also doesn't matter. We're just organizing and orchestrating across the various resources. And so that's really the idea.
Chris Hutchins: What are you saying in what would you tell uh leaders to in terms of where they should be looking to get some traction, but maybe that they're not getting right now?
Andy Moye: Yeah, I mean, I you know, in healthcare specifically, you know, whether it's insolent gene therapy or anything else, I mean, this is where AI makes the most dense on efficiencies and things like this is just sort of the automation of tasks that are that are just simply manual today, you know, and the great example that in healthcare is, you know, the scribes, right? The sort of uh the bridge and you know, you know, Epic has their own and things like this. But you know, giving a doctor a couple hours back of not having to do charts at the end of a day is unbelievably great return of invet return on investment for hospital health system because these doctors now have had life. You know, they're not doing what they used to call pajama time, right? Which was you know, you know, sit in their pajamas at night and do charts and things like that. But now you can look at the you can look at the clinical note that was completely screened, you know, transcribed by AI. And you know, obviously you need to make sure there's nothing hallucinatory in there. It's gotten better, right? These models are getting better, but you need to make sure, and but it takes a lot less time to read through it real quick and go, yep, that's exactly what happened than it was to completely go back and try to remember what did that patient tell me in, you know, like what happened there. So, you know, that's a great efficiency tool. And I think you know, healthcare has actually done a nice job, although it's you know, I don't know what the adoption percentage is, it's still not 50, you know, you know, it's still pretty low numbers percentage-wise, as far as how many hospitals and health systems have adopted it, I think. And then, but ultimately, if you're if you're a leader, whether you're CIO or CTO or whatever, like where am I gonna bring AI? Like, how do you how do you automate tasks? Reimbursement, I mean, we're you know, one of the we're not gonna tackle reimbursement on cell gene therapy initially, but we will eventually. And if you think about that, uh the way that works is well, it doesn't really matter whether you get cell gene therapy, but any kind of drug, prescribe the drug, you have to get some kind of typically prior authorization, if it's any kind of specialty drug, right? Prior authorizations are a paperwork battle, right? You essentially have to prove to the health insurance company that this is necessary, it's medically necessary, it's medically necessary under their coverage guidelines. And today, the companies that have done a great job of using AI are the insurance companies, by the way, because now they have AI screens that screen every input, every prior off application for every drug everywhere, and essentially like are trained to say no. When they're essentially trained to look through them and then compare them and then go, yeah, no, sorry, you know, or okay, maybe, and then push to a human or whatever. But but they use AI bots and agents to screen, but the healthcare systems have it. So the poor healthcare systems, you know, you know, I'm a military guy, poor healthcare systems are bringing the knife to the gunfight, unfortunately, and the insurance companies are winning, right? Because they can when it comes to AI. And so, you know, I also view a world where uh you can move the system faster by as soon as that patient is referred, AI can automatically pull the relevant, you know, look at the insurance, automatically pull the relevant clinical data, automatically generate a medical letter of necessity with 20 different references and everything else, uh, you know, generate the note to the chief medical officer about why this is the other, and then pull three other cases where that same insurer covered the same kind of patient, right? Like all of that and can be sent to the insurance company like that. And then you can have AI agents that also bother their AI agents on a daily basis around where is it? Where is the where's the reimbursement? And again, I look at this world where you're this is waste in the system, Chris, right? It's just it's just waste in the system. You if you can truncate and eliminate this waste, you're getting patients on therapy faster, they're doing better, better patient outcomes. It all works for the system, but the way healthcare is in this country, it's artificially set up to force waste. And that's one of the things we're trying to, you can tackle with AI, I think.
Chris Hutchins: One of the things that bothers me, honestly, is just that the we have a we have a lot of missing information. And the risk of missing data from a biased standpoint to be is probably more unnerving than some of the others, because they're the other, at least in the other ones, you know what you're looking for. hopefully anyway, you have some sense of it. But talk about this from your standpoint. What are the things that get left out today there uh really are a concern when you talk about access inequity and and how do we how do you think about the ways that we could start to make that better? And you know, if there's anything concrete that you see work, I I'd love to hear about that too.
Andy Moye: I mean, you're spot on, right? I mean, this is uh you know, I don't know how long since the days when the first computer came into a hospital system or whatever, or the first digital record happened. The the siloed data, the fragmented data problem persists, right? And I and I think you know, there still hasn't been an answer to this, you know, and of course, Epic now that sort of owns 80% of the large hospital system, you know, electronic medical record and Cerner, and but there's thousands of other electronic medical records for various other systems. And all of that data, no matter what people tell you, is still not flowing from place to place. And it's still not getting to you know, following those patients around in the kind of way that you know you wish it could. I mean, and you know, it's a little bit the question you ask is a little bit like, how big is the elephant we have to eat? And it's like, it's really too big. You know, like I I, you know, as a startup founder, if I was Elon, maybe I could take it on, but I'm not, you know. I'm gonna I want to try to tackle like the end of the tale, you know, like let's see if we can solve this cell and gene therapy fragmented data problem. And that's a big piece of what we're trying to do. It's like all this data is everywhere. Get it in one place and give everybody access to it. I don't have exclusive rights to that data. It's the patient's data, but it's all should be all in one place and it should be visible for research, it should be visible to pharma, it should be visible to the patient, right? The patient's patient's data. And so we should understand what's happening with these really advanced therapies and get all this data in one place, and so that we can make these programs better and that we could get better drugs out. So I, you know, I it's a great question. I mean, the fragmented data and siloed data problem in healthcare, I don't know how long it will persist. Until I don't know how long it will persist. You know, but
Chris Hutchins: if you're starting at a very young age uh and you're teaching people how to be really own the responsibility for taking care of themselves, what are the things you can do that keep you healthy? I mean, we know to at least some high level, but there's just not really been a lot of time invested, I don't think. And if you're aware of it, I'd love to hear, but I think that's an area where long term the best shot we have at fixing some of these things and moving to prevention is we've got to get paid, have some patients. I'm not talking about people, I'm talking about you know, having the tenacity to stick with it and wait, wait it out to see the results long enough to actually then hopefully have something you can make it make a big change from and improve.
Andy Moye: I agree with you, and I think there's a movement, um, at least in younger generations, to be more aware of your own health. Now, now, unfortunately, sometimes that goes the too far the other way. And I saw an influencer that told me to drink, you know, whatever, and then now they're doing that. But uh unfortunately, but at least it's a start, right? Because, you know, to your point, like when I was growing up, and certainly my parents' generation, you went to a doctor when you got sick, that was it. You know, and like, and like, you know, your own health care, you didn't even know what your health records were, you didn't care, you can all this kind of like, but now I do think people want to take more control over their own wellness, unfortunately, you know, to say it that way. Um, you also have Dr. ChatGPT, which causes some of these issues, but but you you you do, I do think there's a movement towards that. It's interesting you say a lot of this stuff because like from a research perspective, the countries where we have the most longitudinal data with the largest populations are almost always you know, social health countries, Iceland or Denmark or the UK, you know, where they actually follow these people for 50 years. You know, the longest heart studies in the world typically tend to come from Scandinavian countries and things like that, because they're usually staying in the same place and they go to the doctor, it's all free. And so it's kind of part of the culture, right, to do that and be part of it. Um, not so in the US, right? It's still such a fragmented system. Who pays for it? Oh, I lost my job, I'm not gonna go see the doctor just to get an update because I got to pay 50 bucks to do it. So, so you know, hopefully, hopefully it's shifting a little bit to more wellness and things like that. But I do agree, it's like preventative care would save so much, so much healthcare dollars in this country, it's unbelievable. For sure.
Chris Hutchins: I don't know.
Andy Moye: You know, and of course what ends up happening to talk one more thing about that, like what ends up happening, I just saw um, and I can't remember who was on the on the panel, but they were talking about GLP-1s versus AI. What's the bigger, you know, what's the bigger breakthrough? And of course, GLP-1s all have their own problems, but you know, from a population health perspective, obesity is a main driver of a lot of chronic conditions. And so you can you could argue that people lose weight and they're better as long as they're healthy, there is a there is a ton of value, you know, to that, but it doesn't change the cultural, like it doesn't change the fast food world we live in. And it, you know, like so I don't know. It's gonna be interesting in the next 10 to 20 years to see if actual population health outcomes get better because of the wellness, at least people trying to take more care of themselves.
Chris Hutchins: Your book is about leadership under pressure. And I think what's so profound is the difference between the kind of pressure you're dealing with running a business versus the kind where a mistake isn't a lost sale. It's somebody's life and maybe the only shot they have at a cure.
Andy Moye: Yep.
Chris Hutchins: What does that what kind of leadership does that demand of a leader that an ordinary tech rollout doesn't?
Andy Moye: Well, that's a really great question. You know, and I think you know, in the military, you know, the training that you get, especially as leaders and officers and things like that, is you know, you you trust your training, you sort of trust the chain of command, and and you know, you always feel qualified for the role that you're in. And so, you know, things, things, you know, you certainly hope, and I, you know, I have colleagues in the military who were in the army and you know, closer to the to the to the bullets than I was. I flew an airplane and I was a pie, you know, and that kind of stuff. But you know, things happen in combat and you you just have to keep moving forward, you know. And I think the mindset around you know knowing that you did what you were supposed to do, that you led with integrity, and that you know, maybe the outcome wasn't this is actually a really great point, Chris, right? One of the things we talk about in the book is, and for leaders in a tech startup or anywhere else, what we like to tend to do is judge the outcomes. Right? So if I have a if I have a sales rep and they lost the deal, right? You go, oh, you lost the deal, you're a bad sales rep, right? But you we all know like a deal, especially if it's a multi-million dollar business-to-business deal, is full of things out of your control or in your control. And so the better way to deal with that situation is to go to sales rep and do a post-mortem and say, well, let's talk about your decision making. Let's talk about your judgment. Let's talk about how did you price? Why did you price it that way? Oh, well, we had we had intel, okay. And when you sort of go and you look at the things that you did that you could control, that's what you need to judge in your people. The outcome is going to be those decisions plus a lot of other factors that are out of your control. That's the outcome. In the military, we do the same thing. And after every mission, you do an after-action review. You used to call them a debrief, and you sit and you don't talk about what happened. You don't say, hey, um, you know, did we win or not win? You say, what did you do? You know, in that moment, Chris, you know, when the you know the ship was calling out, required you to divert, to go do a search and rescue. What, what, why did you make the call to not do that? Or whatever, right? You know, so you start to go through decision making and not about outcome. And that helps to say, okay, well, maybe the next time the decision needs to be, your judgment needs to be different. And that's a different way to lead, right? And I think most leaders, again, in the civilian world or the tech world or whatever, you know, you only judge outcomes, you know, but you don't you don't go back and understand the thought processes. Like Jensen Huang is great about this because he says, what I want people to do is email me and I will give them my thought process. You know, I'm not going to solve their problem, but I'll tell them, well, this is the way I would think about your problem. Right? And for that, and what that allows his managers and people to do is kind of think of it a different way and helps to train their judgment and their decision making. So that would be my answer to you, is like it comes back to you know, trying to ensure you understand how your people are thinking and their judgment. If you have most of the time, if you have really good judgment, really good decision making, you're going to get better outcomes than other people, right?
Chris Hutchins: So if you can just put put your your Nostradamus hat on for a minute, if you could.
Andy Moye: I love this. Yes.
Chris Hutchins: From where you're sitting today, and what you know, the advancements that you know are coming. Yeah, what are you excited about for what you know, but even beyond that, because the possibilities seem to be opening up and the pace seems limitless that we can do.
Andy Moye: Yeah, I you know, I'd love to say like in the next five years, you know, the healthcare system will be so much better. I mean, I don't know, right? It's it is a big slow-moving behemoth beast here in the United States. I do think you know, the idea, you know, so I have a you know, I worked with this guy named Thomas Fuchs, Dr. Thomas Fuchs, brilliant AI guy. He's now the chief AI officer at Eli Lilly. And he framed this the best way, and this is probably the best way to think about AI, right? So if you think about language, human language essentially is let's just call it 50,000 years old. Okay, that's that's how long, and we invented it, right? You know, people invented it. And so so AI, LL. We took that and we can now we're manipulating it. We can we can we can use it. Motion, human, people moving, robotics, right? People moving as a couple hundred thousand years old, maybe a million years old, right? But still kind of young in the in the pantheon of like the universe. And so you start to see robotics and you start to see some of the things that are coming in AI and robotics, and that's kind of interesting. Biology is billions of years old, right? And the problem, the thing with people like AI discovery and drugs and some of the things like it hasn't quite gotten there because it's there are unknowable things. You know, like we still don't know why, for example, when you give anesthesia to a patient, like why it works. Because we don't understand human consciousness, so we don't understand why that puts somebody out and what space they're in. So we don't understand it. But it works, so we use it, right? So so the reality is AI, you know, curing and caught in and bringing you know utopia to the masses is gonna be a while. You know, now AI and robotics, like making things more efficient. I'm super bullish on you know, self-driving cars, you know, all those kind of things for sure. And in healthcare, I am hopeful that we'll start to see data, you know, the conversation we had earlier. I'm hopeful to see AI start to bring some of those data silos together in a way that makes that makes things more efficient. And and ultimately, again, it just goes back to can we get more patients access to care? And if we can, hopefully we start to move the needle from a population health perspective on some of these really tough diseases. So, you know, I I'm a little bullish, I'm a little bearish, you know, on AI and tech, and I think it'll kind of be a combination of those things.
Chris Hutchins: So just before we close this out, uh tell me, what are you launching this this fall with Glidepath? And did tell people where they can find you, where they can learn some more, how they should reach out to you.
Andy Moye: Yeah, I think by the time we'll be out there, we'll have launched our our our uh you know, we're in we've been in stealth mode, we'll be at launch out by the time this episode comes out. So Glidepath Health, uh we're working with a major academic medical center in New York City, which we're super excited about, and have also adopted some of their technology with, and that's Memorial Sloan Kettering. So we're super excited to work with the really the champions. You talk about you know heroes, right? These are these are real true heroes uh at MSK. And so we're always excited to work with them and really start to get this technology into as many hospitals and health systems over the course of the uh the course of the next few years, right? And and so you know, glidepathhealth.com, that's where you can find us, glidepathhealth.com. Uh, for me personally in the book, if folks want to find the book, they can find it at andymoye.com. Uh, you can find it on Amazon, you can find it on Barnes & Noble, um, you can find it on Spotify, audiobooks, so it's there as well. And again, it's from Bunker Hill to the boardroom, battle-tested leadership for today's executives.
Chris Hutchins: Thanks so much for taking the time and coming on the show and for all the great insights that you shared. Uh I cannot wait to see what what's coming next. And I'm certainly gonna follow you, and I just encourage the my my listeners to do the same. Uh, I'll make sure you have everything you need on the show notes to be able to follow what Andy and his team are doing. So that's gonna do it for this episode of the Signal Room, and I look forward to seeing you all next time.